筛状阳性与阴性前列腺癌的主动监测、手术与放疗:PROTECT随机临床试验二次分析
该研究对PROTECT随机临床试验中712例临床局限前列腺癌患者的活检切片进行集中病理回顾,按筛状阳性(浸润性筛状癌和/或导管内癌)分类,分析15年转移风险。结果显示筛状阳性是转移的独立预测因素(HR 3.61),放疗联合新辅助ADT显著降低转移风险(HR 0.35),而手术较主动监测无显著长期获益;筛状阴性患者转移率低且各治疗间无差异。
要点
- 筛状阳性前列腺癌15年转移风险显著增高(HR 3.61)。
- 放疗联合新辅助ADT降低筛状阳性患者转移风险(HR 0.35)。
- 筛状阴性患者转移率低,支持主动监测。
核心结论
- 筛状形态是前列腺癌15年转移的强独立预测因素。
- 放疗联合新辅助ADT与筛状阳性患者长期转移风险降低相关。
- 筛状阴性患者预后良好,支持其适合主动监测。
研究设计与样本
- PROTECT 3期随机临床试验二次分析,纳入1643例临床局限前列腺癌患者。
- 对712例可用诊断活检切片进行集中病理回顾,分类筛状阳性(浸润性筛状癌和/或导管内癌)。
- 患者随机接受主动监测、手术或放疗联合新辅助雄激素剥夺治疗(ADT)。
- 主要结局为转移性疾病进展(影像学骨、内脏或淋巴结转移或PSA>100 ng/mL)。
- 采用多因素Cox比例风险回归和Gray检验,进行意向治疗和符合方案分析。
主要发现
- 712例回顾分析患者中,93例(13.1%)筛状阳性,42例(5.9%)发生转移。
- 筛状阴性患者转移发生率低且不同治疗间无差异。
关键数值与推荐
- 筛状阳性定义:浸润性筛状癌和/或导管内癌。
- 转移定义:影像学骨、内脏或淋巴结转移或PSA>100 ng/mL。
- 筛状阳性患者15年累积转移发生率:放疗联合ADT组8%,手术组26%,主动监测组25%。
临床怎么用
- 对前列腺癌活检病理应评估筛状形态以识别高危患者。
- 筛状阳性患者可考虑放疗联合新辅助ADT以降低长期转移风险。
- 筛状阴性患者转移风险低,适合主动监测。
局限性
- 为回顾性二次分析,仅712例活检切片可用,可能存在选择偏倚。
- 筛状阳性亚组样本量较小(93例),事件数有限。
- 结果需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cribriform prostate cancer is associated with poor outcomes; however, its optimal treatment strategy remains unclear in the absence of randomized data. OBJECTIVE: To retrospectively analyze the results of the PROTECT randomized clinical trial to establish the association between cribriform-positive and cribriform-negative prostate cancer and 15-year risk of metastasis in patients who underwent active monitoring, surgery, or radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: Between 1999 and 2009, the PROTECT phase 3 randomized clinical trial enrolled 1643 men with clinically localized prostate cancer who were randomly assigned to receive active monitoring, surgery, or radiotherapy with neoadjuvant androgen deprivation therapy (ADT). In this secondary analysis of the PROTECT trial, a centralized histopathologic review was conducted on available diagnostic biopsy slides to classify patients as cribriform-positive if they had invasive cribriform carcinoma and/or intraductal carcinoma. Data were collected from January 25, 2024, to October 11, 2024, and were analyzed from October 14, 2024, to January 30, 2025. EXPOSURES: Age, prostate-specific antigen (PSA), Gleason score, and cribriform status. MAIN OUTCOMES AND MEASURES: The primary outcome was progression to metastatic disease (bony, visceral, or lymph node metastases on imaging or PSA >100 ng/mL). Multivariable Cox proportional hazards regression models, adjusted for randomization variables, were incorporated to assess 15-year metastasis risk. Cumulative incidence curves were compared using the Gray test. Both intention-to-treat and per-protocol analyses were performed. RESULTS: Among 712 men (mean [SD] age, 62.0 [5.0] years) whose biopsies were retrospectively reviewed, 93 (13.1%) had cribriform-positive disease and 42 (5.9%) developed metastasis. In the intention-to-treat cohort, cribriform-positive disease significantly increased the risk of metastasis (hazard ratio [HR], 3.61 [95% CI, 1.60-8.11]; P = .003). Radiotherapy with neoadjuvant ADT significantly reduced metastasis risk (HR, 0.35 [95% CI, 0.16-0.78]; P = .04) (15-year cumulative incidence in patients with cribriform-positive disease, 8%), while surgery delayed metastasis but did not significantly improve long-term outcomes compared with active monitoring (HR, 0.52 [95% CI, 0.25-1.08]; P = .09) (15-year cumulative incidence in patients with cribriform-positive disease, 26% for surgery and 25% for active monitoring). Among patients with cribriform-negative disease, incidence of metastasis was low and did not differ by treatment. Similar per-protocol results were noted. CONCLUSIONS AND RELEVANCE: The findings of this secondary analysis of the PROTECT randomized clinical trial suggest that cribriform morphology was a strong, independent predictor of 15-year metastasis among patients with prostate cancer and that radiotherapy with neoadjuvant ADT was associated with a reduced long-term risk of metastasis. Conversely, outcomes were favorable for most patients with cribriform-negative disease, supporting their eligibility for active surveillance. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02044172.
引用
- Sushentsev N, Warren AY, Colling R, et al. Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 41100113. doi:10.1001/jamaoncol.2025.4125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。